原发性胆汁性胆管炎并发骨质疏松的研究现状

赵健; 田浩; 姚定康

doi:10.3969/j.issn.1001-5256.2017.11.039

原发性胆汁性胆管炎并发骨质疏松的研究现状

DOI: 10.3969/j.issn.1001-5256.2017.11.039

第二军医大学长征医院内科学教研室

详细信息

中图分类号: R575.7;R580
计量
- 文章访问数: 1309
- HTML全文浏览量: 14
- PDF下载量: 343
- 被引次数: 0
出版历程
- 收稿日期: 2017-08-18
- 出版日期: 2017-11-20

Research advances in primary biliary cholangitis complicated by osteoporosis

Department of Internal Medicine, Changzheng Hospital, Second Military Medical University

摘要

摘要: 骨质疏松是原发性胆汁性胆管炎的常见并发症,发病率高,骨折风险大,其发病机制尚不明确。回顾了PBC发病机制与治疗的最新进展,研究表明其病因复杂,与多种因素引起的骨质吸收增加、成骨作用减少等相关。虽然已有多种药物应用于临床,但目前最有效的治疗药物是双膦酸盐,未来还需要更多长期的系统性研究以明确其疗效与对骨折事件的影响。
- 胆管炎 /
- 骨质疏松 /
- 综述
Abstract: Osteoporosis is a common complication of primary biliary cholangitis (PBC) with a relatively high prevalence rate and a high risk of bone fracture.The pathogenesis of osteoporosis remains unknown.This article reviews the latest advances in the pathogenesis and treatment of osteoporosis in PBC.Studies have shown that osteoporosis in PBC has various causes, including increased bone absorption and reduced bone formation due to many factors.Although many drugs have been used in clinical practice, until now, bisphosphonates are still the most effective drugs.Long-term systematic studies are needed in the future to clarify their effects on fracture in PBC patients.
- cholangitis /
- osteoporosis /
- review

HTML全文

参考文献(36)

[1]CAREY EJ, ALI AH, LINDOR KD.Primary biliary cirrhosis[J].Lancet, 2015, 386 (10003) :1565-1575.

[2]RUIZ A, MARIA T, GARCIA-BUEY L, et al.Hepatic osteodystrophy in patients with chronic autoimmune cholangiopathies:primary biliary cirrhosis, primary sclerosing cholangitis and autoimmune cholangitis[J].Ann Rheum Dis, 2013, 71 (Suppl 3) :599-599.

[3]LESLIE WD, BERNSTEIN CN, LEBOFF MS.AGA technical review on osteoporosis in hepatic disorders[J].Gastroenterology, 2003, 125 (3) :941-966.

[4]FLOREANI A, MEGA A, CAMOZZI V, et al.Is osteoporosis a peculiar association with primary biliary cirrhosis?[J].World J Gastroenterol, 2005, 11 (34) :5347-5350.

[5]MOUNACH A, OUZZIF Z, WARIAGHLI G, et al.Primary biliary cirrhosis and osteoporosis:a case-control study[J].J Bone Miner Metab, 2008, 26 (4) :379-384.

[6]ZHAO J, LI W, LIANG CQ, et al.Liver cirrhosis and the risk of fracture:a meta-analysis[J].J Clin Hepatol, 2017 (6) :1112-1115. (in Chinese) 赵健, 李伟, 梁才全, 等.肝硬化与骨折发生风险相关性的Meta分析[J].临床肝胆病杂志, 2017 (6) :1112-1115.

[7]GAO XS, DUAN XF.Progress of hepatic osteoporosis in liver cirrhosis[J/CD].Chin J Liver Dis:Electronic Edition, 2015, 7 (4) :14-18. (in Chinese) 高学松, 段雪飞.肝硬化合并肝性骨病的研究进展[J/CD].中国肝脏病杂志:电子版, 2015, 7 (4) :14-18.

[8]ZHAO J, LI W, CAO J, et al.Association between primary biliary cholangitis and fracture:a meta-analysis[J].Clin Res Hepatol Gastroenterol, 2017.[Epub ahead of print]

[9]KOHLI SS, KOHLI VS.Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications[J].Indian J Endocrinol Metab, 2011, 15 (3) :175-181.

[10]DRAKE M T, CLARKE BL, LEWIECKI EM.The pathophysiology and treatment of osteoporosis[J].Clin Ther, 2015, 37 (8) :1837-1850.

[11]HERLONG HF, RECKER RR, MADDREY WC.Bone disease in primary biliary cirrhosis:histologic features and response to 25-hydroxyvitamin D[J].Gastroenterology, 1982, 83 (1 Pt 1) :103-108.

[12]GAO X, ZHANG Y, LIU T, et al.Clinical study of hepatic osteoporosis in primary biliary cirrhosis[J].Hepatol Int, 2017, 11 (1) :s591.

[13]KRISHNAMOORTHY R, GRANT A, SHELDON P, et al.Fracture prevalence and vitamin D status in primary biliary cirrhosis:the Leicestershire experience[J].Gut, 2012, 61 (Suppl 2) :a410-a411.

[14]GUO GY, SHI YQ, WANG L, et al.Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis[J].Aliment Pharmacol Ther, 2015, 42 (2) :221-230.

[15]PARES A, GUANABENS N.Osteoporosis in primary biliary cirrhosis:pathogenesis and treatment[J].Clin Liver Dis, 2008, 12 (2) :407-424.

[16]ANGULO P, JORGENSEN RA, KEACH JC, et al.Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid[J].Hepatology, 2000, 31 (2) :318-323.

[17]GUICHELAAR MM, MALINCHOC M, SIBONGA J, et al.Bone metabolism in advanced cholestatic liver disease:analysis by bone histomorphometry[J].Hepatology, 2002, 36 (1) :895-903.

[18]RUIZ-GASPA S, GUANABENS N, ENJUANES A, et al.Lithocholic acid downregulates vitamin D effects in human osteoblasts[J].Eur J Clin Invest, 2010, 40 (1) :25-34.

[19]KOSHIHARA Y, HOSHI K, OKAWARA R, et al.Vitamin Kstimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture[J].J Endocrinol, 2003, 176 (3) :339-348.

[20]COLLIER JD, NINKOVIC M, COMPSTON JE.Guidelines on the management of osteoporosis associated with chronic liver disease[J].Gut, 2002, 50 (Suppl 1) :1-9.

[21]KEMMLER W, ENGELKE K, von STENGEL S.Long-term exercise and bone mineral density changes in postmenopausal womenare there periods of reduced effectiveness?[J].J Bone Miner Res, 2016, 31 (1) :215-222.

[22]BLACK DM, ROSEN CJ.Clinical practice.Postmenopausal osteoporosis[J].N Engl J Med, 2016, 374 (3) :254-262.

[23]SHIOMI S, MASAKI K, HABU D, et al.Calcitriol for bone disease in patients with cirrhosis of the liver[J].J Gastroenterol Hepatol, 1999, 14 (6) :547-552.

[24]SHIOMI S, MASAKI K, HABU D, et al.Calcitriol for bone loss in patients with primary biliary cirrhosis[J].J Gastroenterol, 1999, 34 (2) :241-245.

[25]GUANABENS N, CERDA D, MONEGAL A, et al.Low bone mass and severity of cholestasis affect fracture risk in patients with primary biliary cirrhosis[J].Gastroenterology, 2010, 138 (7) :2348-2356.

[26]JANSEN JP, BERGMAN GJ, HUELS J, et al.The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis:a network meta-analysis[J].Semin Arthritis Rheum, 2011, 40 (4) :275-284.

[27]GUANABENS N, PARES A, ROS I, et al.Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis[J].Am J Gastroenterol, 2003, 98 (10) :2268-2274.

[28]ZEIN CO, JORGENSEN RA, CLARKE B, et al.Alendronate improves bone mineral density in primary biliary cirrhosis:a randomized placebo-controlled trial[J].Hepatology, 2005, 42 (4) :762-771.

[29]RUDIC JS, GILJACA V, KRSTIC MN, et al.Bisphosphonates for osteoporosis in primary biliary cirrhosis[J].Cochrane Database Syst Rev, 2011 (12) :d9144.

[30]GUANABENS N, MONEGAL A, CERDA D, et al.Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis[J].Hepatology, 2013, 58 (6) :2070-2078.

[31]RUDIC JS, POROPAT G, KRSTIC MN, et al.Hormone replacement for osteoporosis in women with primary biliary cirrhosis[J].Cochrane Database Syst Rev, 2011, 12 (12) :d9146.

[32]MENON KV, ANGULO P, BOE GM, et al.Safety and efficacy of estrogen therapy in preventing bone loss in primary biliary cirrhosis[J].Am JGastroenterol, 2003, 98 (4) :889-892.

[33]PEREIRA SP, O'DONOHUE J, MONIZ C, et al.Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis:results of a 1-year controlled trial[J].Aliment Pharmacol Ther, 2004, 19 (5) :563-570.

[34]LEVY C, HARNOIS DM, ANGULO P, et al.Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis:results of a pilot study[J].Liver Int, 2005, 25 (1) :117-121.

[35]FLOREANI A, CHIARAMONTE M, GIANNINI S, et al.Longitudinal study on osteodystrophy in primary biliary cirrhosis (PBC) and a pilot study on calcitonin treatment[J].J Hepatol, 1991, 12 (2) :217-223.

[36]FLOREANI A, ZAPPALA F, FRIES W, et al.A 3-year pilot study with 1, 25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis[J].J Clin Gastroenterol, 1997, 24 (4) :239-244.

施引文献

资源附件(0)

访问统计